Update: Iterum Therapeutics Q4 Adjusted EPS $(0.81) Beats $(0.94) Estimate
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics (NASDAQ:ITRM) reported Q4 adjusted EPS losses of $(0.81), surpassing the analyst consensus estimate of $(0.94) by 13.83%. However, this represents a 55.77% increase in losses compared to $(0.52) per share from the same period last year.
March 28, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Iterum Therapeutics reported a smaller-than-expected Q4 loss per share, but its losses have significantly widened compared to the previous year.
While beating EPS estimates typically has a positive impact on stock prices, the significant year-over-year increase in losses could temper investor enthusiasm. The mixed results make the short-term impact on ITRM's stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100